The Health Inequality Data Repository (HIDR) includes nearly 11...
Category:
Health
Latest
Scorching temperatures hit Asia’s power grids, raise region’s health risks
While this time of year is typically the hottest for India and...
India’s heatwaves putting economy, development goals at risk – study
Extreme heat has caused more than 24,000 deaths since 1992 and has...
Dip in new COVID-19 cases, India records 29,163 infections in single day
The number of active cases remained below 5 lakh for the seventh consecutive day.There are 4,53,401 active cases of coronavirus infection in the country as?on date?which comprises 5.11 per cent of the total caseload,the data stated.?
The total recoveries have surged to 82,90,370 pushing the national recovery rate to 93.42 per cent,while the COVID-19 case fatality rate stands at 1.47 per cent
Normalcy may return by winter 2021, says COVID-19 vaccine creator
A new COVID vaccine’s impact will work significantly over the summer and life should be back to normal by next winter, Prof Ugur Sahin, co-founder of BioNTech, whose vaccine candidate has proved to prevent over 90 per cent people from getting Covid-19, as per preliminary reports. The Pfizer-BioNTech is one of the 11 vaccines in their final tests.
This winter would still be hard, he said in an interview on the BBC’s Andrew Marr Show.
Moderna says its COVID-19 Vaccine is over 94% effective
A preliminary analysis of data from more than 30,000 volunteers showed Moderna’s vaccine prevented virtually all symptomatic cases of Covid-19, the disease caused by the coronavirus, the company said in a statement on Monday.
A key advantage of Moderna’s vaccine is that it does not need ultra-cold storage like Pfizer’s, making it easier to distribute. Moderna expects it to be stable at standard refrigerator temperatures of 2-8 degrees Celsius (36-48°F) for 30 days and it can be stored for up to 6 months at -20 degrees Celsius.
Insurers need to deploy integrated digital ecosystems to elevate customer experience:dacadoo
Many insurers have failed to fully grasp the magnitude of the changes that are happening,” explains Peter Ohnemus, President & CEO of the Health and Insurtech firm dacadoo, which provides digital health engagement and health risk quantification systems to insurers.
“
Insurers cannot provide unlimited cover in pandemic, UK Supreme Court told
The case revolves around whether 21 policy wordings, affecting potentially 700 types of policies, 60 insurers, 370,000 policyholders and billions of pounds in claims, should cover disruption caused by the virus.
The wordings cover business interruption when insured premises cannot be accessed because of public authority restrictions, in the event of a notifiable disease within a specified radius and hybrid wordings.
Cybersecurity is top business worry in ‘age of risk’: Marsh & McLennan CEO
“CEOs like to get things done and say it’s finished,” he said. “Cyber is a never-ending phenomenon. It will continue for the rest of all of our careers.”
Climate change and the culture of remote working are the other top risks cited by companies, Glaser said. Climate is less immediate than cybersecurity because it is developing slowly and its impact, through such catastrophic events as larger wildfires and more powerful hurricanes, will increase over the next five years or more.
Medical costs of discharged COVID patients 50% above pre-admission levels:German study
The coronavirus proved especially dangerous for people with heart disease, high blood pressure or respiratory diseases, the study showed.
Where social distancing comes naturally: Finland keeps coronavirus in check
“We like to be in solitude wandering the forests and swimming in the lakes, so many Finns have actually enjoyed that they have been able to move away from the cities,” Kristian Wahlbeck, director of the Finnish Association for Mental Health (MIELI), said.
Breakthrough COVID vaccine tech could help defeat other diseases
Moderna and BioNTech, for example, are also applying mRNA technology to experimental cancer medicines.
“Stunningly Impressive”: On Moderna Covid Vaccine Results
The vaccine is based on a relatively new technology that uses a synthetic version of a molecule called “messenger RNA” to hack into human cells, and effectively turn them into vaccine-making factories.
No vaccine based on this platform has ever been approved.